Immunotherapy for nasopharyngeal cancer can achieve certain efficacy in some advanced patients, especially those with positive PD-L1 expression, which can make the patient’s tumor shrink or stabilize without progression, and prolong the progression-free time. Nasopharyngeal cancer is a common malignant tumor of the head and neck, and early stage patients are mainly treated with radical radiotherapy and surgery, and some patients can be cured. However, once nasopharyngeal cancer develops into advanced stage, the possibility of patients to get cured is obviously reduced. At present, some clinical studies have confirmed that the use of immune drugs for third-line or back-line treatment of nasopharyngeal cancer, or immunotherapy combined with chemotherapy in the first-line treatment of advanced nasopharyngeal cancer with PD-L1 positive expression, can have the effect of tumor shrinkage, and some patients can get the prolongation of the survival period.